Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020069621 - NOVEL BIOMARKER FOR ALZHEIMER'S DISEASE IN HUMAN

Publication Number WO/2020/069621
Publication Date 09.04.2020
International Application No. PCT/CA2019/051417
International Filing Date 03.10.2019
IPC
G01N 33/68 2006.01
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
68involving proteins, peptides or amino acids
CPC
G01N 2440/14
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2440Post-translational modifications [PTMs] in chemical analysis of biological material
14phosphorylation
G01N 2800/2814
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2800Detection or diagnosis of diseases
28Neurological disorders
2814Dementia; Cognitive disorders
G01N 2800/2821
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2800Detection or diagnosis of diseases
28Neurological disorders
2814Dementia; Cognitive disorders
2821Alzheimer
G01N 2800/50
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2800Detection or diagnosis of diseases
50Determining the risk of developing a disease
G01N 2800/52
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2800Detection or diagnosis of diseases
52Predicting or monitoring the response to treatment; Prognosis
G01N 33/6896
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48Biological material, e.g. blood, urine
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
68involving proteins, peptides or amino acids
6893related to diseases not provided for elsewhere
6896Neurological disorders, e.g. Alzheimer's disease
Applicants
  • UNIVERSITY OF MANITOBA [CA]/[CA]
Inventors
  • SABBIR, Mohammad Golam
Agents
  • ADE & COMPANY INC.
Priority Data
62/741,14804.10.2018US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) NOVEL BIOMARKER FOR ALZHEIMER'S DISEASE IN HUMAN
(FR) NOUVEAU BIOMARQUEUR POUR LA MALADIE D'ALZHEIMER CHEZ L'ÊTRE HUMAIN
Abstract
(EN)
The present invention relates to an in vitro method for determining the risk of developing Alzheimer's disease or a cognitive disorder similar to said disease, an in vitro method for designing a personalized therapy in a subject suffering from mild cognitive impairment and an in vitro method for selecting a patient susceptible to be treated with a therapy for the prevention and/or treatment of Alzheimer's or a cognitive disorder similar to said disease based on determining, in a sample from the subject, the level of phosphorylation in serine, tyrosine and/or threonine residues of interest in transferrin protein or in a functionally equivalent variant. The invention also relates to the use of transferrin protein or a functionally equivalent variant thereof, wherein the transferrin protein or variant is phosphorylated as a marker of the risk of developing Alzheimer's disease or a cognitive disorder similar to Alzheimer's disease. Finally, the invention relates to a kit comprising a reagent capable of determining the level of phosphorylation in residues of interest of transferrin protein and the use of said kit.
(FR)
La présente invention concerne un procédé in vitro de détermination du risque de développement de la maladie d'Alzheimer ou d'un trouble cognitif similaire à ladite maladie, un procédé in vitro de conception d'une thérapie personnalisée chez un sujet souffrant d'une déficience cognitive légère et un procédé in vitro de sélection d'un patient susceptible d'être traité avec une thérapie pour la prévention et/ou le traitement de la maladie d'Alzheimer ou d'un trouble cognitif similaire à ladite maladie sur la base de la détermination, dans un échantillon provenant du sujet, du niveau de phosphorylation dans les résidus de sérine, de tyrosine et/ou de thréonine d'intérêt dans la protéine transferrine ou dans une variante fonctionnellement équivalente. L'invention concerne également l'utilisation de la protéine transferrine ou d'une variante fonctionnellement équivalente de celle-ci, la protéine transferrine ou variante étant phosphorylée en tant que marqueur du risque de développement de la maladie d'Alzheimer ou d'un trouble cognitif similaire à la maladie d'Alzheimer. Enfin, l'invention concerne un kit comprenant un réactif capable de déterminer le niveau de phosphorylation dans des résidus d'intérêt de la protéine transferrine et l'utilisation dudit kit.
Latest bibliographic data on file with the International Bureau